SRTS

Sensus Healthcare, Inc.
  • Healthcare
  • Medical - Devices
  • $52M market cap
Forecast run · Sep 14, 2026Upside rank 1367 of 3,136

Model Signal

ForecastQ Daily Probabilities
38.0%
49.7%
16.8%

Analyst Consensus

Recommendation2.33/5 Buy
Last price$3.15
Price target$4.75
Implied move+50.8%
Analysts9

ForecastQ Portfolios

SRTS is not in any ForecastQ portfolio today. The model scores it with every run; the names it picked are in Portfolios.

Company Profile

Sensus Healthcare, Inc. operates as a medical technology enterprise, manufacturing and distributing radiation therapy apparatuses to medical institutions across the globe. The company's portfolio leverages superficial radiation therapy (SRT), a cutting-edge low-energy X-ray methodology. Their product line features the SRT-100, a photon X-ray system for low-energy superficial radiotherapy. This device presents a non-surgical alternative for patients dealing with non-melanoma skin cancers, including basal cell and squamous cell carcinomas, alongside other dermatological issues like keloids. Another key offering is the SRT-100 Vision, which incorporates a specialized SRT treatment planning application. This application seamlessly integrates an embedded high-frequency ultrasound imaging module, tools for volumetric tumor analysis, beam margin delineation, and dosimetry parameter configuration. In addition, Sensus Healthcare provides the SRT-100 Plus, the Sentinel service program to ensure system protection for its clients, and options for in-office laser rentals. They also supply various consumable items, such as replacement lead shielding, disposable radiation safety gear like aprons and eye shields, ultrasound probe film, and single-use applicator tips designed to treat lesions of different sizes and on various body areas. Founded in 2010, Sensus Healthcare, Inc. maintains its corporate headquarters in Boca Raton, Florida.

ForecastQ

Quantitative stocks signals powered by AI


The information provided is for educational purposes only and should not be considered financial advice. Past performance is not indicative of future results. ForecastQ is a research platform, a living documentation of an engineering experiment. We are not financial advisors.


© ForecastQ. All rights reserved.